Vertex Competitors

Stocks Mexico . 
Stock . Vertex Pharmaceuticals
VRTX Stock  MXN 8,150  42.60  0.53%   
Vertex Pharmaceuticals competes with FibroGen, McEwen Mining, Promotora, and Boeing; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Vertex Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Vertex Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Vertex Pharmaceuticals Correlation with its peers.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Vertex Pharmaceuticals competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
8,1478,1508,153
Details
Intrinsic
Valuation
LowRealHigh
7,3007,3038,965
Details

Vertex Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Vertex Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Vertex and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Vertex Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
USB
+ 0.8
PINFRAL
NOV
+ 0.8
BA
TSMN
+ 0.75
USB
TSMN
+ 0.74
PINFRAL
BOLSAA
+ 0.72
NOV
BA
+ 0.7
PINFRAL
  
High negative correlations   
FGEN
- 0.41
VRTX
BA
- 0.33
VRTX
MUX
- 0.29
FGEN
NOV
- 0.29
VRTX
TSMN
- 0.13
FGEN
BOLSAA
- 0.13
FGEN

Risk-Adjusted Indicators

There is a big difference between Vertex Stock performing well and Vertex Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vertex Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VRTX  1.34 (0.12) 0.00  0.25  0.00 
 0.00 
 3.91 
(3.83)
 23.29 
FGEN  2.99  0.47  0.05  0.65  3.77 
(11.48)
 12.62 
(10.45)
 33.83 
MUX  0.58  0.28  0.00  12.37  0.00 
 0.00 
 0.00 
 0.00 
 19.28 
PINFRAL  1.09  0.40  0.23 (24.08) 0.61 
(1.89)
 3.40 
(1.61)
 6.89 
BA  1.67  0.25  0.12  0.72  1.74 
(1.89)
 4.06 
(3.21)
 8.46 
NOV  0.01  0.00  0.00  0.63  0.00 
 0.00 
 0.00 
 0.00 
 0.47 
USB  0.90  0.29  0.08 (0.66) 0.70 
(5.24)
 3.34 
(0.80)
 17.91 
BOLSAA  1.36  0.11  0.04  2.04  1.70 
(1.47)
 4.05 
(2.83)
 11.26 
IBM  1.08  0.13  0.05  1.28  1.21 
(1.76)
 3.19 
(3.06)
 8.21 
TSMN  1.94  0.30  0.12  0.55  2.08 
(2.10)
 3.89 
(4.01)
 15.02 
All Fundamental Data

Vertex Pharmaceuticals Competitive Analysis

The better you understand Vertex Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Vertex Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Vertex Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
VRTX FGEN MUX PINFRAL BA NOV USB BOLSAA IBM TSMN
 0.53 
 8,150 
Vertex
 26.74 
 10.19 
FibroGen
 0.00 
 198.00 
McEwen
 0.67 
 149.99 
Promotora
 1.80 
 3,550 
Boeing
 0.00 
 322.44 
NOV
 4.28 
 1,004 
USB
 0.03 
 33.65 
Bolsa
 3.33 
 4,476 
International
 1.08 
 4,140 
Taiwan
Market Volatility
(90 Days Market Risk)
Very steady
Moderately volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
OK
Solid
Good
OK
OK
Insignificant
Insignificant
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Average
Low
Low
Low
Low
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Fairly Valued
Fairly Valued
Fairly Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Sell
Strong Buy
Strong Sell
Strong Buy
Cautious Hold
Sell
Hold
Hold
Strong Hold
Current Ratio
4.61
6.16
1.99
7.9
1.35
3.3
N/A
3.99
1.83
1.88
Net Asset
18.15 B
773.82 M
525.34 M
N/A
137.1 B
10.13 B
674.8 B
8.59 B
127.24 B
4.96 T
Profit Margin
0.37
-2.94
-0.55
27.13
-0.0741
0.0214
0.26
0.45
0.0271
0.45
EBITDA
4.29 B
(288.53 M)
(32.45 M)
5.94 B
(510 M)
598 M
N/A
2.41 B
7.17 B
753.4 B
Operating Margin
0.49
-2.52
-0.67
51.89
-0.005
0.0365
0.35
0.56
0.12
0.5
Current Valuation
1.41 T
21.87 B
5.28 B
40.76 B
3.03 T
185.2 B
1.82 T
18.49 B
3.57 T
7.54 T
Price To Book
6.07
54.45
0.5
0.87
N/A
1.49
1.61
3.06
6.68
4.6
Five Year Return
N/A
N/A
N/A
N/A
2.39
2.13
2.24
4.16
3.4
2.8
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
959.08 B
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
812.49 B
Beta
0.46
0.85
1.25
0.54
1.41
1.89
1.0
0.73
0.85
1.26
Number Of Employees
4.8 K
566
430
2.83 K
156 K
22
77 K
385
46
72
Shares Outstanding
257.09 M
93.96 M
47.43 M
49.42 M
598.24 M
392.8 M
1.53 B
578.31 M
904.13 M
5.19 B
Cash Flow From Operations
2.64 B
(82.23 M)
(20.22 M)
4.78 B
3.51 B
(179 M)
9.87 B
1.79 B
10.44 B
1.61 T
Annual Yield
N/A
N/A
0.0048
N/A
0.0017
0.0086
0.0394
0.0548
0.0496
0.0188
Total Debt
893.85 M
77.14 M
48.87 M
16.46 B
51.67 B
1.72 B
39.83 B
270.21 M
46.19 B
610.07 B
Return On Equity
0.28
-1.85
-0.16
6.34
N/A
0.0304
0.11
0.27
0.0869
0.4
Z Score
N/A
N/A
67.8
1.8
27.6
62.4
21.0
50.4
29.4
9.0
Return On Asset
0.17
-0.27
-0.0904
4.28
-0.0015
0.0168
0.0094
0.16
0.0363
0.16
Book Value Per Share
54.13
0.28
7.59
109.68
-26.58
13.13
28.71
12.34
24.23
14.2
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
235.89 B
Total Asset
18.15 B
773.82 M
525.34 M
N/A
137.1 B
10.13 B
674.8 B
8.59 B
127.24 B
4.96 T
Debt To Equity
0.097
15.1
11.3
0.3
N/A
24.0
N/A
0.038
440.5
0.21
Last Dividend Paid
N/A
N/A
N/A
4.73
N/A
0.2
1.88
2.16
6.59
N/A
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
N/A
48.78
N/A
N/A
Shares Owned By Institutions
96.96
78.8
22.1
19.54
57.49
95.64
73.18
48.93
58.08
17.63
Market Capitalization
1.46 T
43.36 B
5.53 B
60.38 B
2.42 T
179.03 B
1.4 T
22.79 B
2.3 T
9.38 T
Price To Earning
17.5
N/A
34.68
11.88
940.25
-109.14
241.57
16.51
296.56
31.17
Price To Earnings To Growth
0.41
N/A
N/A
3.57
6.11
N/A
0.83
1.55
1.26
0.83
Price To Sales
180.7
231.63
43.04
6.07
35.18
25.89
59.47
5.56
43.04
3.79
Net Income
3.32 B
(290.02 M)
(56.71 M)
2.7 B
(4.93 B)
155 M
5.83 B
1.6 B
1.64 B
1.02 T
Earnings Per Share
238.31
-62.14
-2.8
7.99
-167.98
7.39
69.33
3.07
36.64
122.68
Shares Owned By Insiders
0.2
7.82
17.61
N/A
0.09
0.65
0.12
N/A
0.09
N/A
Revenue
8.93 B
235.31 M
136.54 M
9.94 B
66.61 B
7.24 B
24.18 B
3.92 B
60.53 B
2.26 T
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
576.6 B
Cash And Equivalents
6.71 B
565.4 M
15.49 M
27.7 B
21.34 B
1.27 B
18.76 B
3.31 B
46.27 B
870.84 B
Cash Per Share
25.86
6.56
0.04
64.49
36.41
3.29
11.9
5.59
52.21
167.92
Gross Profit
7.55 B
(104.61 M)
4.88 M
5.14 B
5.77 B
1.33 B
22.21 B
1.97 B
32.69 B
1.35 T
Day Typical Price
8125.0
10.11
198.0
149.99
3550.0
322.44
1004.5
33.62
4476.0
4155.0
Accumulation Distribution
0.0092
271.51
N/A
N/A
N/A
N/A
N/A
4037.57
N/A
4.03
Market Facilitation Index
75.0
3.0E-4
N/A
N/A
N/A
N/A
N/A
0.0
N/A
0.12
Daily Balance Of Power
0.568
2.5
0.0
(9,223,372,036,855)
(9,223,372,036,855)
0.0
(9,223,372,036,855)
0.0127
(9,223,372,036,855)
(1.00)
Period Momentum Indicator
42.6
2.15
N/A
(1.01)
(65.00)
N/A
(44.94)
0.01
(154.00)
(45.00)
Rate Of Daily Change
1.01
1.27
1.0
0.99
0.98
1.0
0.96
1.0
0.97
0.99
Day Median Price
8112.5
10.07
198.0
149.99
3550.0
322.44
1004.5
33.61
4476.0
4162.5
Price Action Indicator
58.8
1.19
N/A
(0.50)
(32.50)
N/A
(22.47)
0.05
(77.00)
(44.99)
Coefficient Of Variation
(2,351)
1212.74
812.4
359.94
752.56
812.4
750.84
1661.86
1130.11
775.76
Mean Deviation
1.34
2.99
0.5753
1.09
1.67
0.0141
0.8999
1.36
1.08
1.94
Jensen Alpha
(0.12)
0.4749
0.2813
0.4004
0.2543
(0)
0.2931
0.1096
0.1332
0.303
Total Risk Alpha
(0.27)
0.2322
0.179
0.3357
0.1766
(0.01)
0.1843
0.0238
0.0648
0.211
Sortino Ratio
N/A
0.0487
N/A
0.2285
0.118
N/A
0.0805
0.041
0.049
0.1208
Downside Variance
N/A
91.82
N/A
2.55
3.88
N/A
9.17
3.51
4.35
5.71
Standard Deviation
2.98
6.21
2.37
1.48
2.09
0.0583
2.17
2.02
1.66
2.59
Kurtosis
12.81
6.29
66.0
0.8791
(0.43)
66.0
23.22
3.31
2.3
2.39
Potential Upside
3.91
12.62
N/A
3.4
4.06
N/A
3.34
4.05
3.19
3.89
Treynor Ratio
0.2457
0.6496
12.37
(24.08)
0.7156
0.6275
(0.66)
2.04
1.28
0.5505
Maximum Drawdown
23.29
33.83
19.28
6.89
8.46
0.4736
17.91
11.26
8.21
15.02
Variance
8.87
38.52
5.63
2.18
4.35
0.0034
4.69
4.08
2.76
6.69
Market Risk Adjusted Performance
0.2557
0.6596
12.38
(24.07)
0.7256
0.6375
(0.65)
2.05
1.29
0.5605
Risk Adjusted Performance
(0.03)
0.0746
0.105
0.2267
0.1124
(0.03)
0.1128
0.0542
0.0759
0.11
Skewness
(2.38)
1.24
8.12
0.5842
(0.02)
8.12
3.85
0.3412
0.528
0.7027
Semi Deviation
N/A
3.77
N/A
0.6086
1.74
N/A
0.6956
1.7
1.21
2.08
Information Ratio
(0.06)
0.0753
0.1042
0.2475
0.1114
(0.64)
0.1125
0.038
0.0616
0.1116
Value At Risk
(3.83)
(10.45)
N/A
(1.61)
(3.21)
N/A
(0.80)
(2.83)
(3.06)
(4.01)
Expected Short fall
N/A
(11.48)
N/A
(1.89)
(1.89)
N/A
(5.24)
(1.47)
(1.76)
(2.10)
Downside Deviation
N/A
9.58
N/A
1.6
1.97
N/A
3.03
1.87
2.09
2.39
Semi Variance
N/A
14.24
N/A
0.3704
3.03
N/A
0.4838
2.9
1.47
4.33

Vertex Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Vertex Pharmaceuticals Competition

Vertex Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Vertex Pharmaceuticals in relation to its competition. Vertex Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Vertex Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Vertex Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Vertex Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Vertex Pharmaceuticals position

In addition to having Vertex Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Value Funds Thematic Idea Now

Small Value Funds
Small Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 31 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY